Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Yen Y, et al. Among authors: raschko j. Cancer Chemother Pharmacol. 2002 Nov;50(5):353-9. doi: 10.1007/s00280-002-0492-9. Epub 2002 Sep 12. Cancer Chemother Pharmacol. 2002. PMID: 12439592 Clinical Trial.
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
Morgan RJ Jr, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, Leong L, Margolin K, Niland J, Raschko J, Somlo G, Carroll M, Chow W, Tetef M, Hamasaki V, Yen Y, Doroshow JH. Morgan RJ Jr, et al. Among authors: raschko j. Cancer Chemother Pharmacol. 2003 Jun;51(6):459-64. doi: 10.1007/s00280-003-0605-0. Epub 2003 Apr 15. Cancer Chemother Pharmacol. 2003. PMID: 12695856 Clinical Trial.
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ Jr, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Morgan RJ Jr, et al. Among authors: raschko j. Cancer Chemother Pharmacol. 2004 Oct;54(4):283-9. doi: 10.1007/s00280-004-0818-x. Epub 2004 Jun 4. Cancer Chemother Pharmacol. 2004. PMID: 15184995 Clinical Trial.
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Akman SA, Ahn C, Nagasawa S, et al. Somlo G, et al. Among authors: raschko jw. Cancer. 1994 Mar 15;73(6):1678-85. doi: 10.1002/1097-0142(19940315)73:6<1678::aid-cncr2820730621>3.0.co;2-u. Cancer. 1994. PMID: 7512436 Clinical Trial.
Phase I study of mitomycin C and menadione in advanced solid tumors.
Margolin KA, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko JW, Ahn C, Doroshow JH. Margolin KA, et al. Among authors: raschko jw. Cancer Chemother Pharmacol. 1995;36(4):293-8. doi: 10.1007/BF00689046. Cancer Chemother Pharmacol. 1995. PMID: 7628048 Clinical Trial.
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, Forman SJ, Margolin KA, Morgan RJ, Leong LA, et al. Somlo G, et al. Among authors: raschko jw. J Clin Oncol. 1995 May;13(5):1231-7. doi: 10.1200/JCO.1995.13.5.1231. J Clin Oncol. 1995. PMID: 7738626 Clinical Trial.
52 results